The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates

Investigations using models of neurologic disease frequently involve quantifying animal motor activity. We developed a simple method for measuring motor activity using a computer-based video system (the Webcam system) consisting of an inexpensive video camera connected to a personal computer running customized software. Images of the animals are captured at half-second intervals and movement is quantified as the number of pixel changes between consecutive images. The Webcam system allows measurement of motor activity of the animals in their home cages, without devices affixed to their bodies. Webcam quantification of movement was validated by correlation with measures simultaneously obtained by two other methods: measurement of locomotion by interruption of infrared beams; and measurement of general motor activity using portable accelerometers. In untreated squirrel monkeys, correlations of Webcam and locomotor activity exceeded 0.79, and correlations with general activity counts exceeded 0.65. Webcam activity decreased after the monkeys were rendered parkinsonian by treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), but the correlations with the other measures of motor activity were maintained. Webcam activity also correlated with clinical ratings of parkinsonism. These results indicate that the Webcam system is reliable under both untreated and experimental conditions and is an excellent method for quantifying motor activity in animals.

[1]  A Eschalier,et al.  Assessment of motor behavior using a video system and a clinical rating scale in parkinsonian monkeys lesioned by MPTP , 2001, Journal of Neuroscience Methods.

[2]  Takashi Kato,et al.  A new video/computer method to measure the amount of overall movement in experimental animals (two-dimensional object-difference method) , 1999, Journal of Neuroscience Methods.

[4]  A. Imperato,et al.  The Antioxidant Ebselen Prevents Neurotoxicity and Clinical Symptoms in a Primate Model of Parkinson's Disease , 2000, Experimental Neurology.

[5]  D. Togasaki,et al.  The hyperkinetic abnormal movements scale: A tool for measuring levodopa‐induced abnormal movements in squirrel monkeys , 2002, Movement disorders : official journal of the Movement Disorder Society.

[6]  A. Benazzouz,et al.  Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. , 1995, European journal of pharmacology.

[7]  M. Herrero,et al.  Measurement of motor disability in MPTP-treated macaques using a telemetry system for estimating circadian motor activity , 2004, Journal of Neuroscience Methods.

[8]  J. Langston,et al.  Investigating levodopa-induced dyskinesias in the parkinsonian primate. , 2000, Annals of neurology.

[9]  O. Hornykiewicz.  Biochemical aspects of Parkinson's disease , 1998, Neurology.

[10]  J. Langston,et al.  The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey , 1990, Brain Research.

[11]  C. Rebert,et al.  Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.

[12]  P. Bédard,et al.  Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. , 1993, Clinical neuropharmacology.

[13]  M Wangenheim,et al.  A device for three-dimensional registration of human movement. , 1987, Ergonomics.

[14]  Z. Zhang,et al.  Developing a stable bilateral model of parkinsonism in rhesus monkeys , 1993, Neuroscience.

[15]  R. Kurlan,et al.  Oral levodopa dose‐response study in MPTP‐induced hemiparkinsonian monkeys: Assessment with a new rating scale for monkey parkinsonism , 1991, Movement disorders : official journal of the Movement Disorder Society.

[16]  J. Mazziotta,et al.  Differential recovery of volitional motor function, lateralized cognitive function, dopamine agonist-induced rotation and dopaminergic parameters in monkeys made hemi-parkinsonian by intracarotid MPTP infusion , 1995, Brain Research.

[17]  J. Holden,et al.  Age‐related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys , 1998, The Journal of comparative neurology.

[18]  P. Jenner,et al.  Chronic L‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix jacchus) , 1995, Movement disorders : official journal of the Movement Disorder Society.

[19]  T. Chase,et al.  Levodopa‐induced dyskinesias improved by a glutamate antagonist in parkinsonia monkeys , 1996 .

[20]  E. Bézard,et al.  Effect of the D3 Dopamine Receptor Partial Agonist BP897 [N-[4-(4-(2-Methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on l-3,4-Dihydroxyphenylalanine-Induced Dyskinesias and Parkinsonism in Squirrel Monkeys , 2004, Journal of Pharmacology and Experimental Therapeutics.

[21]  S. Konitsiotis,et al.  Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. , 1997, The Journal of pharmacology and experimental therapeutics.